Question explored with the scientific record
Best treatment to cure: prostate cancer T3b N1 MO Gleason 4+5
T3b N1 M0 with Gleason 4+5 is high-risk, node-positive disease. There is no single proven "cure." The strongest combination evidence favors radiation plus long-term hormone therapy.
Node-positive prostate cancer has no clean head-to-head trial here that settles the best cure. What the retrieved records show is that adding radiation to hormone therapy in node-positive men improved cancer-specific survival at 8 years (92% versus 86% with hormones alone) [4]. The STAMPEDE data in node-positive nonmetastatic disease shows radiotherapy clearly improved failure-free survival [6]. Surgery can be done in locally advanced disease but comes with real leakage of urine and erectile harm, and biochemical recurrence by 3 years ran around 70% [2].
| Approach | Key outcome (from records) |
|---|---|
| RT + hormone therapy | 8-year cancer-specific survival 92% [4] |
| Hormones alone | 86% [4] |
| Surgery, locally advanced | ~70% recurrence-free at 3 years [2] |
One honest structural note: the comparison records here are mostly observational, not randomized [4][5]. Node-positive men with Gleason 9 were underrepresented in these cohorts. Node removal itself has no proven survival benefit and carries real complication risk [1][3]. The strongest evidence base still lacks a clean vaccinated-to-unvaccinated equivalent: RT+ADT versus modern surgery+RT in Gleason 4+5 N1 has not been run head-to-head in the records surfaced here.
My call: for a Gleason 4+5 N1 M0 man, the best-supported curative-intent path in this evidence is external beam radiation covering pelvis plus long-term androgen deprivation, not surgery alone. Confidence: moderate.
Sources used 6
-
Is het doen van een pelviene lymfeklierdissectie bij prostaatkanker nog wel gerechtvaardigd nu PSMA PET/CT breed beschikbaar is?
No study convincingly demonstrates long-term oncological benefit of pelvic lymph-node dissection in prostate cancer, while PSMA PET/CT approaches its diagnostic accuracy.
DOI: 10.1007/s13629-025-00479-z -
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis
Radical prostatectomy with extended pelvic lymph node dissection is feasible as a primary treatment for locally advanced prostate cancer, achieving about 70% biochemical recurrence-free survival at 3 years with acceptable short-term morbidity, suggesting RP can be a viable alter…
DOI: 10.1016/j.urology.2005.12.003 -
PELVIC LYMPH NODE DISSECTION IN PROSTATE CANCER: BALANCING DIAGNOSTIC BENEFIT AND COMPLICATIONS IN THE ERA OF PSMA PET/CT
Pelvic lymph node dissection in prostate cancer remains a trade-off: extended dissection improves nodal staging but raises lymphocele, lymphedema and nerve-injury risk, while PSMA PET/CT may allow selective omission.
DOI: 10.71217/uju.2(10).2026.18-25 -
Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer
This study investigates the impact of adjuvant radiotherapy on cancer-specific mortality in patients with node-positive prostate cancer, revealing that the benefits are significantly influenced by tumor characteristics.
DOI: 10.1200/JCO.2013.54.7893 -
Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN 1 prostate cancer treated with radical prostatectomy
Adjuvant radiation therapy after radical prostatectomy for lymph node–positive prostate cancer improves biochemical recurrence-free and metastasis-free survival compared with salvage radiation therapy or no treatment, with early salvage RT showing better metastasis control than …
DOI: 10.1111/bju.13679 -
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer
This study analyzes the survival outcomes and the impact of radiotherapy on failure-free survival in patients with newly diagnosed high-risk nonmetastatic prostate cancer from the control arm of the STAMPEDE trial, revealing that radiotherapy significantly improves failure-free …
DOI: 10.1001/jamaoncol.2015.4350